행사/교육
Biomarkers World Europe 2011
- 등록일2010-11-10
- 조회수2499
- 구분 국외
- 행사교육분류 행사
-
주관기관
Health Network Communications Ltd
-
행사장소
Olympia Conference Centere London, UK
-
행사기간
2011-05-17 ~ 2011-05-20
- 원문링크
-
첨부파일
Biomarkers World Europe 2011
Biomarkers World is Europe's most comprehensive event covering the strategic use of biomarkers
Biomarkers World Europe will cover the critical issues regarding the strategic use of biomarkers in drug discovery and development. Strategic and technical sessions will provide valuable information on how to add value to your R&D plans.
For delegates
The pressures on pharmaceutical R&D to deliver are greater than ever. Costs are spiralling yet productivity is falling. Bottlenecks in R&D continue to have a significant impact on the ability of the industry to speed winning products to the market.
Biomarkers offer the unprecedented opportunity to alleviate these major pressures and enrich the drug discovery and development process. Biomarkers World Europe will review and address the key challenges in the use of biomarkers to develop more effective and targeted treatments.
About the event
Biomarkers have long been hailed as the saviour for pharmaceutical R&D. It is perhaps no surprise that the global biomarker market is estimated to be $20.5 billion by 2014.
However, several key questions remain:
- How can biomarkers deliver value?
- How are they being used to reduce attrition rates?
- What are the obstacles that need to be overcome to deliver a coherent strategy across
discovery and development?
Biomarkers World Europe will cover the critical issues in strategic use of biomarkers in drug discovery and development.
Biomarkers World Europe, co-located with Exploratory Clinical Development World, will form part of Europe’s largest R&D strategy congress in Europe. The event now in its fifth year, regularly attracts a high number of early development scientists and decision makers, that explore the challenges of Phase I trials. There is no other way to make sure you are on top of the many issues within early phase drug development.
.......(계속)
☞ 자세한 내용은 내용바로가기를 이용하시기 바랍니다.